[2] QURESHI A, OUATTARA L A, EISAYED N S, et al. Synthesis and evaluation of anti-HIV activity of mono- and di-substituted phosphonamidate conjugates of tenofovir [J]. Molecules, 2022, 27(14): 4447.
[3] SEVENLER D, BARDON A, FERNANDEZ S M, et al. Immunoassay for HIV drug metabolites tenofovir and tenofovir diphosphate [J]. ACS Infectious Diseases, 2020, 6(7): 1635-1642.
[4] TSENG C H, HSU Y C, CHEN T H, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis[J]. The Lancet Gastroenterology and Hepatology,2020,5(12): 1039-1052.
[5] LIM J, CHOI W M, SHIM J H, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na?ve chronic hepatitis B [J]. Liver International, 2022, 42(7): 1517-1527.
[6] LI Y P, YANG B, QUAN Y N, et al. Advancement of prodrug approaches for nucleotide antiviral agents [J]. Current Topics in Medicinal Chemistry, 2021, 21(32): 2909-2927.
[7] KALCIC F, ZGARBOVA M, HODEK J, et al. Discovery of modified amidate (ProTide) prodrugs of tenofovir with enhanced antiviral properties [J]. Journal of Medicinal Chemistry, 2021, 64(50): 16425-16449.
[8] 尚胜捷, 王璨, 陈云峰. 抗病毒药物中间体替诺福韦的合成工艺研究 [J]. 武汉工程大学学报, 2022, 44(6): 619-623, 663.
[9] AMBLARD F, PATEL D, MICHAILIDIS E, et al. HIV nucleoside reverse transcriptase inhibitors [J]. European Journal of Medicinal Chemistry, 2022, 240: 114554.
[10] 张杰, 施务务, 葛少波, 等. 替诺福韦的合成工艺研究 [J]. 世界最新医学信息文摘, 2015, 15(50): 130.
[11] 王志刚, 聂静, 王治国. 泰诺福韦的合成工艺研究 [J]. 湖北理工学院学报, 2015, 31(5): 46-49.
[12] 刘嘉, 李科, 孙海玲, 等. 替诺福韦的合成工艺改进 [J]. 药学实践杂志, 2009, 27(1): 31-32.
[13] 李陈, 杨芳, 郭建琼, 等. 替诺福韦的合成工艺优化研究 [J]. 化学研究与应用, 2018, 30(6): 970-973.
[14] DIETZ J P, FERENC D, JAMISON T F, et al. Di-tert-butyl phosphonate route to the antiviral drug tenofovir [J]. Organic Process Research & Development, 2021, 25 (4): 789-798.
[15] ZHANG Q Q, PENG Y M, HOU J, et al. An O-benzyl phosphonamidate prodrug of tenofovir for the treatment of hepatitis B virus infection [J]. European Journal of Medicinal Chemistry, 2022, 65 (13): 9493-9505.
[16] RILEY D L, WALWYN D R, EDLIN C D. An improved process for preparation of tenofovir disoproxil fumarate [J]. Organic Process Research & Development, 2016, 20(4): 742-750.
[17] YOSHIDA Y, HONMA M, KIMURA Y, et al. Structure, synthesis and inhibition mechanism of nucleoside analogues as HIV‐1 reverse transcriptase inhibitors (NRTIs) [J]. Journal of Medicinal Chemistry, 2021, 16 (5): 743-766.
[18] YANG J T, LI Z, HU F F, et al. Synthesis of multimeric impurities of tenofovir disoproxil fumarate [J]. Organic Preparations and Procedures International, 2019, 51 (4): 397-402.
[19] DERSTINE B P, TOMLIN J W, PECK C L, et al. An efficient synthesis of tenofovir (PMPA): a key intermediate leading to tenofovir-based HIV medicines [J]. Organic Process Research & Development, 2020, 24?(8): 1420-1427.
[20] MANDALA D, THOMPSON W A, WATTS P. Synthesis routes to anti-HIV drugs [J]. Tetrahedron Letters, 2016, 72 (24): 3389-3420.
[21] SUVEGES N S, RODRIGUEZ A A, DIEDERICHS C C, et al. Continuous-flow synthesis of (R)-propylene carbonate: an important intermediate in the synthesis of tenofovir [J]. European Journal of Organic Chemistry, 2018, 2018 (23): 2931-2938.
[22] WANG A P, WU S, TAO Z Y, et al. Design, synthesis, and anti-HBV activity of new bis(L-amino acid) ester tenofovir prodrugs [J]. ACS Medicinal Chemistry Letters, 2019, 10 (6): 991-995.